Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.82 |
| ▸ | ERBB2 | P04626 | 13/20 | 0.77 |
| ▸ | ERBB4 | Q15303 | 9/20 | 0.77 |
| ▸ | JAK3 | P52333 | 2/20 | 0.74 |
| ▸ | GAK | O14976 | 1/20 | 0.74 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.74 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.74 |
| ▸ | LCK | P06239 | 1/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.74 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.74 |
| ▸ | SRC | P12931 | 1/20 | 0.74 |
| ▸ | DRD2 | P14416 | 1/20 | 0.74 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.74 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.74 |
| ▸ | MC3R | P41968 | 1/20 | 0.74 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.74 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.74 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1191597 | 1.00 | EGFR (0.82) | EGFRERBB2ERBB4JAK3GAK | |
| SCHEMBL1191694 | 0.99 | EGFR (0.82) | EGFRERBB2ERBB4JAK3GAK | |
| SCHEMBL1191693 | 0.99 | EGFR (0.82) | EGFRERBB2ERBB4JAK3GAK | |
| SCHEMBL14427863 | 0.98 | EGFR (0.81) | EGFRERBB2ERBB4JAK3GAK | |
| SCHEMBL14427864 | 0.97 | EGFR (0.81) | EGFRERBB2ERBB4JAK3GAK | |
| SCHEMBL14066529 | 0.96 | EGFR (0.82) | EGFRERBB2ERBB4JAK3GAK | |
| SCHEMBL14066620 | 0.95 | EGFR (0.85) | EGFRERBB2ERBB4JAK3GAK | |
| SCHEMBL3578587 | 0.94 | EGFR (0.84) | EGFRERBB2ERBB4JAK3GAK | |
| SCHEMBL3578586 | 0.94 | EGFR (0.84) | EGFRERBB2ERBB4JAK3GAK | |
| SCHEMBL3578951 | 0.94 | EGFR (0.85) | EGFRERBB2ERBB4JAK3GAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1731511-B1 | Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof | BOEHRINGER INGELHEIM PHARMA (DE) | 2015-08-12 | — | — | EP | claimed |
| US-20100010023-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-01-14 | — | — | US | claimed |
| EP-2112140-A1 | Chinazolin derivatives, medicine containing these compounds, application thereof and method for their production | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2009-10-28 | — | — | EP | claimed |
| US-20060100223-A1 | Quinazoline derivatives and pharmaceutical compositions containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-05-11 | — | — | US | claimed |
| EP-1345910-A1 | QUINAZOLINE DERIVATIVES, MEDICAMENTS CONTAINING SAID COMPOUNDS, THEIR UTILIZATION AND METHOD FOR THE PRODUCTION THEREOF | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-09-24 | — | — | EP | claimed |
| US-20020173509-A1 | Quinazoline derivatives and phamaceutical compositions containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-11-21 | — | — | US | claimed |
| WO-2002050043-A1 | QUINAZOLINE DERIVATIVES, MEDICAMENTS CONTAINING SAID COMPOUNDS, THEIR UTILIZATION AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-06-27 | — | — | WO | claimed |
| EP-1731511-B1 | Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof | BOEHRINGER INGELHEIM PHARMA (DE) | 2015-08-12 | — | — | EP | disclosed |
| US-8722694-B2 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2014-05-13 | — | — | US | disclosed |
| US-8586608-B2 | Quinazoline derivatives and pharmaceutical compositions containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2013-11-19 | — | — | US | disclosed |
| US-20120329778-A1 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESSES FOR PREPARING THEM | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2012-12-27 | — | — | US | disclosed |
| US-RE43431-E1 | Quinazoline derivatives and pharmaceutical compositions containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2012-05-29 | — | — | US | disclosed |
| US-20110046168-A1 | METHODS OF TREATING DISEASES USING QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2011-02-24 | — | — | US | disclosed |
| US-7019012-B2 | Tyrosine inhibitors; antitumor agents; respiratory system disorders | BOEHRINGER INGELHEIM INTERNATIONAL PHARMA GMBH & CO. KG (DE) | 2006-03-28 | — | — | US | disclosed |
| EP-1345910-A1 | QUINAZOLINE DERIVATIVES, MEDICAMENTS CONTAINING SAID COMPOUNDS, THEIR UTILIZATION AND METHOD FOR THE PRODUCTION THEREOF | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-09-24 | — | — | EP | disclosed |
| US-20020173509-A1 | Quinazoline derivatives and phamaceutical compositions containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-11-21 | — | — | US | disclosed |
| US-20020169180-A1 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-11-14 | — | — | US | disclosed |
| WO-2002050043-A1 | QUINAZOLINE DERIVATIVES, MEDICAMENTS CONTAINING SAID COMPOUNDS, THEIR UTILIZATION AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-06-27 | — | — | WO | disclosed |
| EP-1194418-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND METHODS FOR THE PRODUCTION THEREOF | Boehringer Ingelheim Pharma KG (DE) | 2002-04-10 | — | — | EP | disclosed |
| WO-2000078735-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND METHODS FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173509-A1 | Quinazoline derivatives and phamaceutical compositions containing them | MAP3K1, MAP4K2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | EGFR 195/4885ERBB2 78/4885ERBB4 152/4885 |
| US-20060100223-A1 | Quinazoline derivatives and pharmaceutical compositions containing them | CNKSR1, RET, ABL1 | EGFR 200/4885ERBB2 122/4885ERBB4 130/4885 |
| US-20120329778-A1 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESSES FOR PREPARING THEM | RET, ROR1, JAK1 | EGFR 100/4885ERBB2 57/4885ERBB4 230/4885 |
| US-20100010023-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CNKSR1, ABL1, TYK2 | EGFR 218/4885ERBB2 109/4885ERBB4 138/4885 |
| US-20020169180-A1 | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | CYP11B1, ROR1, RET | EGFR 75/4885ERBB2 31/4885ERBB4 241/4885 |
| US-20110046168-A1 | METHODS OF TREATING DISEASES USING QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CNKSR1, ABL1, JAK1 | EGFR 212/4885ERBB2 100/4885ERBB4 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.